InduPro Secures $77M Series B, Launches First Human Cancer Trial

Seattle and Cambridge, Mass.-based biotech startup InduPro has secured $77 million in Series B funding and simultaneously initiated the first human clinical trial for its lead cancer drug candidate, IDP-001. This dual announcement marks a significant advancement for the four-year-old company as it pursues a novel, precision-focused approach to targeting tumor cells.

The substantial Series B funding round was spearheaded by The Column Group, with notable participation from a syndicate of leading life sciences investors. These include Vida Ventures, MRL Ventures Fund, Emerson Collective, Euclidean Capital, Solasta Ventures, and pharmaceutical giants Sanofi and Eli Lilly and Company. InduPro CEO Prakash Raman highlighted that this backing underscores investor confidence in the potential of their "proximity-guided platform" to deliver targeted therapeutics across oncology and autoimmune diseases. The newly raised capital will be instrumental in advancing the Phase 1 development of IDP-001 and expanding the company's preclinical pipeline.

Advancing to Human Trials

A critical milestone accompanies the funding news: InduPro has dosed its first patient in a Phase 1 clinical trial for IDP-001. This experimental antibody-drug conjugate is engineered to precisely attack cancer cells by recognizing specific combinations of two proteins found in close proximity on their surface. The early-stage trial is designed to evaluate the drug's safety, tolerability, and pharmacokinetics, while also seeking early indicators of antitumor activity in adult patients.

Targeting Advanced Cancers with Precision

The current Phase 1 trial is recruiting individuals diagnosed with advanced or metastatic non-small cell lung cancer and other solid tumors. These patients have typically seen their disease progress despite receiving standard treatments, highlighting the urgent need for new therapeutic options. InduPro's innovative ARRIS platform aims to address this challenge by leveraging the spatial relationships between proteins, enabling drugs to differentiate and selectively target cancer cells while sparing healthy tissue.

Leading InduPro's efforts are CEO Prakash Raman, a seasoned biopharma executive who previously held leadership roles at Ribon Therapeutics and Novartis, and President and Chief Scientific Officer Scott Lesley, formerly VP of Discovery Biologics at Merck.

Strategic Collaborations and Future Outlook

The company's scientific prowess has also attracted significant industry attention, evidenced by a strategic collaboration and licensing agreement signed with Eli Lilly earlier this year. This potentially lucrative deal, valued at up to approximately $950 million, covers the development of up to three oncology targets using InduPro's advanced platform.

InduPro's ability to secure substantial funding and initiate human trials within four years of its inception underscores the rapid progress and perceived promise of its technology. The combination of its novel targeting approach, a robust investor base, and a major pharmaceutical partnership positions InduPro as a significant player to watch in the evolving landscape of precision oncology and autoimmune disease research. Future developments will hinge on the initial safety and efficacy data emerging from the IDP-001 Phase 1 trial, paving the way for further clinical advancement.

FAQ

Q: What is InduPro's unique approach to cancer treatment?

A: InduPro develops drugs based on the spatial relationships of proteins on cell surfaces, using its ARRIS platform. This allows them to identify combinations of targets that are close together on cancer cells but not on normal tissue, potentially enabling drugs to selectively attack tumors with greater precision.

Q: What type of cancer is InduPro's lead drug, IDP-001, designed to treat?

A: IDP-001 is being tested in a Phase 1 clinical trial for adults with advanced or metastatic non-small cell lung cancer and other solid tumors that have progressed after standard treatment.

Q: How will the new $77 million funding be used by InduPro?

A: The Series B funding will support the ongoing Phase 1 clinical development of IDP-001 and further advance InduPro's preclinical pipeline, which includes programs targeting both cancer and autoimmune diseases.